D. Price Et Al. , "Lower pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone," RESPIROLOGY , pp.81, 2022
Price, D. Et Al. 2022. Lower pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone. RESPIROLOGY , 81.
Price, D., Henley, W., Carter, V., Skinner, D., Vella, R., Papi, A., ... Fabbri, L.(2022). Lower pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone. RESPIROLOGY , 81.
Price, D. Et Al. "Lower pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone," RESPIROLOGY , 81, 2022
Price, D. Et Al. "Lower pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone." RESPIROLOGY , pp.81, 2022
Price, D. Et Al. (2022) . "Lower pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone." RESPIROLOGY , p.81.
@article{article, author={D. Price Et Al. }, title={Lower pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone}, journal={RESPIROLOGY}, year=2022, pages={81} }